冠状动脉粥样硬化性心脏病的治疗新方向——PCSK9抑制剂

New Direction of Coronary Atherosclerotic Heart DiseaseTreatment—PCSK9 Inhibitors

血脂异常,尤其是低密度脂蛋白胆固醇的升高,是冠状动脉粥样硬化性心脏病的主要危险因素之一。他汀类降脂药物因其多种副作用,不能完全满足临床的需要。前蛋白转化酶枯草溶菌素9抑制剂,通过抑制前蛋白转化酶枯草溶菌素9与低密度脂蛋白胆固醇受体的结合,降低血液中低密度脂蛋白胆固醇水平,从而有效地降低冠状动脉粥样硬化性心脏病事件的发生率,改善临床预后。

Dyslipidemia,especially the rise of low-density lipoprotein cholesterol,is one of the main risk factor of coronary atherosclerotic heart disease.Traditional statins can't meet people's needs completely because of their various side effects.Proprotein convertase subtilisin/kexin type 9 inhibitor can effectively reduce the incidence of coronary atherosclerotic heart disease and improve the clinical prognosis by inhibiting the binding of proprotein convertase subtilisin/kexin type 9 to low-density lipoprotein receptor.